REYON Pharmaceutical Co., Ltd. Stock price

Equities

A102460

KR7102460003

Pharmaceuticals

End-of-day quote Korea S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
15,500 KRW -0.77% Intraday chart for REYON Pharmaceutical Co., Ltd. -4.56% -6.29%
Sales 2021 143B 106M Sales 2022 154B 114M Capitalization 384B 285M
Net income 2021 5.54B 4.1M Net income 2022 7.43B 5.51M EV / Sales 2021 5.19 x
Net Debt 2021 110B 81.41M Net Debt 2022 174B 129M EV / Sales 2022 3.63 x
P/E ratio 2021
116 x
P/E ratio 2022
53.2 x
Employees 463
Yield 2021
0.7%
Yield 2022
0.69%
Free-Float 42.72%
More Fundamentals * Assessed data
Dynamic Chart
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
REYON Pharmaceutical Co., Ltd. announced that it has received KRW 10 billion in funding CI
REYON Pharmaceutical Co., Ltd. announced that it expects to receive KRW 10 billion in funding CI
Tranche Update on REYON Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 6, 2018. CI
REYON Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 6, 2018 has expired with 240,840 shares, representing 1.44% for KRW 4,975.65 million. CI
Tranche Update on REYON Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 6, 2018. CI
REYON Pharmaceutical Co., Ltd. announces an Equity Buyback for KRW 5,000 million worth of its shares. CI
REYON Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
More news
1 day-0.77%
1 week-4.56%
Current month+3.68%
1 month+5.80%
3 months-3.12%
6 months-2.58%
Current year-6.29%
More quotes
1 week
15 400.00
Extreme 15400
16 490.00
1 month
14 670.00
Extreme 14670
16 500.00
Current year
14 120.00
Extreme 14120
17 150.00
1 year
13 960.00
Extreme 13960
20 800.00
3 years
13 960.00
Extreme 13960
77 700.00
5 years
6 794.12
Extreme 6794.1176
77 700.00
10 years
6 794.12
Extreme 6794.1176
77 700.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 73 -
Chief Executive Officer 50 -
Sales & Marketing 54 -
Members of the board TitleAgeSince
Chief Executive Officer 50 -
Director/Board Member 80 -
Chief Executive Officer 73 -
More insiders
Date Price Change Volume
24-03-27 15,500 -0.77% 20 638
24-03-27 15,620 -2.01% 37,783
24-03-26 15,940 -1.60% 31,209
24-03-25 16,200 +0.50% 38,094
24-03-22 16,120 +0.44% 51,872

End-of-day quote Korea S.E., March 27, 2024

More quotes
REYON PHARMACEUTICAL Co. Ltd. is a Korea-based company engaged in the provision of pharmaceutical products. The Company's products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. It also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.
More about the company
  1. Stock
  2. Equities
  3. Stock REYON Pharmaceutical Co., Ltd. - Korea S.E.